PPARA and hypertrophic cardiomyopathy: Additionally, we enriched the PPAR signaling pathway in the up-down group, the hypertrophic cardiomyopathy (HCM) in the up-unchanged group, the transcriptional dysregulation in cancer in the down-up group, and the complement and coagulation cascade in the unchanged-up group.